Related Experiment Video

Updated: Nov 25, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.3K

Tumor mutational burden as a tissue-agnostic biomarker for cancer immunotherapy

Winnie W Y Sung1, James C H Chow1, William C S Cho1

  • 1Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China.

Expert Review of Clinical Pharmacology
|December 16, 2020
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Cancer immunotherapytissue-agnostic biomarkertumor mutational burden

More Related Videos

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.9K
Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors06:32

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors

Published on: August 18, 2023

2.6K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
884